Kun Chen1, Zhiyuan Wu1, Mengya Zang1, Ce Wang2, Yanmei Wang1, Dongmei Wang1, Yifan Ma2, Chunfeng Qu1,3. 1. Department of Immunology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100021, China. 2. Guangdong Key Laboratory of Nanomedicine, Key Lab of Health Informatics of Chinese Academy of Sciences, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences Shenzhen 518055, China. 3. State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing 100021, China.
Abstract
BACKGROUND: Glypican-3 (GPC3) is one of the key tissue markers that could discriminate malignant precancerous lesions from benign hepatic lesions in cirrhotic patients. We aimed to develop a GPC3 cancer vaccine to induce specific T cells to intervene in hepatocellular carcinoma (HCC) development. METHODS: Synthesizing mannosylated liposomes (LPMan) as vaccine delivery system, incorporating one Toll-like receptor (TLR)-7/8 agonist CL097 as adjuvant, we prepared a GPC3 nanovaccine, LPMan-GPC3/CL097. We injected 25 mg/kg diethylnitrosamine intraperitoneally to induce autochthonous HCC in HBV-transgenic mice, which persistently express hepatitis B surface antigen in hepatocytes. Starting from week 8 after diethylnitrosamine injection when malignant hepatocytes generated, we immunized the mice subcutaneously every 2 weeks 4 times with LPMan-GPC3/CL097 containing 5 µg of GPC3 plus 5 µg of CL097. RESULTS: The vaccine efficiently targeted draining lymph nodes where naïve T cells reside and enhanced the expression of molecules involved in antigen presentation in migratory dendritic cells (DCs). Antigen was professionally processed in endoplasmic reticulum-Golgi system of DCs, subsequently priming both CD4+ and CD8+ T cells. The LPMan-GPC3/CL097 immunization generated significantly more GPC3-specific CD4+ IFNγ- and CD8+ IFNγ-producing T cells in mice spleens and livers, which specifically eliminated GPC3-expressing tumor cells. One week after last immunization (week 15 after diethylnitrosamine), 5/5 un-immunized, 5/5 sham (LPMan-CL097) and 1/5 LPMan-GPC3/CL097-immunized mice developed HCC. By week 20 after diethylnitrosamine, significantly less HCC developed in LPMan-GPC3/CL097-immunized mice than in sham-immunized mice (P<0.01). CONCLUSIONS: LPMan-GPC3/CL097 immunization induced de novo generation of specific T cells against tumor-associated antigen GPC3 that could prevent HCC development in cirrhotic liver.
BACKGROUND:Glypican-3 (GPC3) is one of the key tissue markers that could discriminate malignant precancerous lesions from benign hepatic lesions in cirrhotic patients. We aimed to develop a GPC3cancer vaccine to induce specific T cells to intervene in hepatocellular carcinoma (HCC) development. METHODS: Synthesizing mannosylated liposomes (LPMan) as vaccine delivery system, incorporating one Toll-like receptor (TLR)-7/8 agonist CL097 as adjuvant, we prepared a GPC3 nanovaccine, LPMan-GPC3/CL097. We injected 25 mg/kg diethylnitrosamine intraperitoneally to induce autochthonous HCC in HBV-transgenic mice, which persistently express hepatitis B surface antigen in hepatocytes. Starting from week 8 after diethylnitrosamine injection when malignant hepatocytes generated, we immunized the mice subcutaneously every 2 weeks 4 times with LPMan-GPC3/CL097 containing 5 µg of GPC3 plus 5 µg of CL097. RESULTS: The vaccine efficiently targeted draining lymph nodes where naïve T cells reside and enhanced the expression of molecules involved in antigen presentation in migratory dendritic cells (DCs). Antigen was professionally processed in endoplasmic reticulum-Golgi system of DCs, subsequently priming both CD4+ and CD8+ T cells. The LPMan-GPC3/CL097 immunization generated significantly more GPC3-specific CD4+ IFNγ- and CD8+ IFNγ-producing T cells in mice spleens and livers, which specifically eliminated GPC3-expressing tumor cells. One week after last immunization (week 15 after diethylnitrosamine), 5/5 un-immunized, 5/5 sham (LPMan-CL097) and 1/5 LPMan-GPC3/CL097-immunized mice developed HCC. By week 20 after diethylnitrosamine, significantly less HCC developed in LPMan-GPC3/CL097-immunized mice than in sham-immunized mice (P<0.01). CONCLUSIONS: LPMan-GPC3/CL097 immunization induced de novo generation of specific T cells against tumor-associated antigen GPC3 that could prevent HCC development in cirrhotic liver.
Entities:
Keywords:
Cancer vaccine; T cells; hepatocellular carcinoma; murine model; tumor-associated antigen
Authors: Guobin He; Debanjan Dhar; Hayato Nakagawa; Joan Font-Burgada; Hisanobu Ogata; Yuhong Jiang; Shabnam Shalapour; Ekihiro Seki; Shawn E Yost; Kristen Jepsen; Kelly A Frazer; Olivier Harismendy; Maria Hatziapostolou; Dimitrios Iliopoulos; Atsushi Suetsugu; Robert M Hoffman; Ryosuke Tateishi; Kazuhiko Koike; Michael Karin Journal: Cell Date: 2013-10-10 Impact factor: 41.582
Authors: Yuan Hong; Yibing Peng; Z Sheng Guo; Jose Guevara-Patino; Junfeng Pang; Lisa H Butterfield; Nahid F Mivechi; David H Munn; David L Bartlett; Yukai He Journal: Hepatology Date: 2014-02-18 Impact factor: 17.425
Authors: M Geissler; L Mohr; R Weth; G Köhler; C F Grimm; T U Krohne; F von Weizsäcker; H E Blum Journal: Gastroenterology Date: 2001-10 Impact factor: 22.682
Authors: F V Chisari; C A Pinkert; D R Milich; P Filippi; A McLachlan; R D Palmiter; R L Brinster Journal: Science Date: 1985-12-06 Impact factor: 47.728
Authors: Patrick A Ott; Zhuting Hu; Derin B Keskin; Sachet A Shukla; Jing Sun; David J Bozym; Wandi Zhang; Adrienne Luoma; Anita Giobbie-Hurder; Lauren Peter; Christina Chen; Oriol Olive; Todd A Carter; Shuqiang Li; David J Lieb; Thomas Eisenhaure; Evisa Gjini; Jonathan Stevens; William J Lane; Indu Javeri; Kaliappanadar Nellaiappan; Andres M Salazar; Heather Daley; Michael Seaman; Elizabeth I Buchbinder; Charles H Yoon; Maegan Harden; Niall Lennon; Stacey Gabriel; Scott J Rodig; Dan H Barouch; Jon C Aster; Gad Getz; Kai Wucherpfennig; Donna Neuberg; Jerome Ritz; Eric S Lander; Edward F Fritsch; Nir Hacohen; Catherine J Wu Journal: Nature Date: 2017-07-05 Impact factor: 49.962
Authors: Pedro Romero; Jacques Banchereau; Nina Bhardwaj; Mark Cockett; Mary L Disis; Glenn Dranoff; Eli Gilboa; Scott A Hammond; Robert Hershberg; Alan J Korman; Pia Kvistborg; Cornelis Melief; Ira Mellman; A Karolina Palucka; Irina Redchenko; Harlan Robins; Federica Sallusto; Theodore Schenkelberg; Stephen Schoenberger; Jeffrey Sosman; Özlem Türeci; Benoît Van den Eynde; Wayne Koff; George Coukos Journal: Sci Transl Med Date: 2016-04-13 Impact factor: 17.956
Authors: Rose M Berman; Olivia J Kelada; Nicholas T Gutsche; Raju Natarajan; Rolf E Swenson; Ying Fu; Jessica Hong; Mitchell Ho; Peter L Choyke; Freddy E Escorcia Journal: Cancer Biother Radiopharm Date: 2019-08-19 Impact factor: 3.099